Published by Global Banking & Finance Review®
Posted on June 12, 2025
1 min readLast updated: January 23, 2026
Novo Nordisk will start late-stage trials for its obesity drug amycretin in 2026, targeting overweight adults with a dual hormone action.
(Reuters) -Novo Nordisk said on Thursday it plans to start late-stage trials of its experimental weight-loss drug amycretin in injection and oral forms during the first quarter of 2026 for adults who are overweight or obese.
The decision to advance the trials is based on feedback received from regulatory authorities in interactions following the end of its mid-stage trials, the company said.
Amycretin, the Danish drugmaker's next generation obesity drug, has a dual mode action. Like its popular weight-loss drug Wegovy, amycretin mimics the gut hormone GLP-1, but it also mimics the effect of a hunger-suppressing pancreatic hormone called amylin.
(Reporting by Harshita Meenaktshi and Sriparna Roy in Bengaluru; Editing by Leroy Leo)
Novo Nordisk plans to start late-stage trials of amycretin in the first quarter of 2026.
The decision to advance the trials is based on feedback received from regulatory authorities following the end of its mid-stage trials.
Amycretin mimics the gut hormone GLP-1 and has a dual mode of action, similar to Novo Nordisk's popular weight-loss drug Wegovy.
Explore more articles in the Headlines category
